NCT00533065

Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

Effects of the Cholinesterase Inhibitor Donepezil on Organic and Functional Deficits Associated With Age-Related Decrease of Growth Hormone

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Ludwig Boltzmann Gesellschaft · Academic / Other
• Sex: All
• Age: 70 Years – 80 Years
• Healthy volunteers: Accepted

Summary

The planned study has two purposes: 1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year. 2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .

Conditions

• Elderly

Interventions

Type	Name	Description
DRUG	Donepezil	week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)

Timeline

• Start date: 2007-09-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2007-09-21
• Last updated: 2009-08-07

Locations

1 site across 1 country: Austria